Valuation: EnteroMedics Inc

Market Cap 11.09M 9.95M 9.09M 8.3M 15.63M 1.04B 16.13M 110M 43.69M 556M 41.62M 40.73M 1.76B P/E 2026 *
-2.43x
P/E 2027 * -1.98x
Enterprise Value 11.09M 9.95M 9.09M 8.3M 15.63M 1.04B 16.13M 110M 43.69M 556M 41.62M 40.73M 1.76B EV / Sales 2026 *
108x
EV / Sales 2027 * 55.4x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 103K 92.38K 84.43K 77.07K 145K 9.68M 150K 1.02M 406K 5.17M 387K 378K 16.31M 200K 179K 164K 150K 282K 18.8M 291K 1.98M 788K 10.03M 751K 735K 31.67M
Net income -4.49M -4.03M -3.68M -3.36M -6.33M -422M -6.53M -44.35M -17.68M -225M -16.85M -16.49M -711M -7.85M -7.04M -6.43M -5.87M -11.06M -738M -11.41M -77.52M -30.91M -394M -29.45M -28.82M -1.24B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-